Effects of 24-week Toll-like receptor 9 agonist treatment in HIV type 1+ individuals.
Vibholm LK, Konrad CV, Schleimann MH, Frattari G, Winckelmann A, Klastrup V, Jensen NM, Jensen SS, Schmidt M, Wittig B, Zuwala K, Mack K, Olesen R, Hua S, Lichterfeld M, Østergaard L, Denton PW, Tolstrup M, Søgaard OS.
Vibholm LK, et al. Among authors: sogaard os.
AIDS. 2019 Jul 1;33(8):1315-1325. doi: 10.1097/QAD.0000000000002213.
AIDS. 2019.
PMID: 30932955
Clinical Trial.